Track Biktarvy price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Biktarvy Costs $3,746.00 Per Claim
Biktarvy (Bictegravir/Emtricitabine/TAF) is used to treat hiv. According to CMS Medicare Part D spending data, the program spent $3.8B on this drug, covering 85,000 beneficiaries across 1,020,000 claims.
This drug is currently protected by patents expiring Feb 7, 2033. Until patent protection ends, no generic version can enter the market, which limits price competition. Once generics become available, the price typically drops 80-95%.
Spending on Biktarvy increased by +12.8% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Biktarvy (Bictegravir/Emtricitabine/TAF) costs an average of $3,746.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $44,953.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Biktarvy averages $3,746.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Biktarvy reflects in our Medicare Part D average of $3,746.00 per claim. No generic is available yet, so cost remains at brand-name pricing. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Biktarvy, but coverage varies by formulary tier. Biktarvy is often Tier 2 or Tier 3 on most formularies, meaning a higher copay than generic alternatives. Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Patient assistance programs are the primary affordability path while no generic is available.
Biktarvy is still under patent protection until Feb 7, 2033, giving the manufacturer market exclusivity. Once the patent expires, generics enter the market and prices typically fall 80-95% within 1-2 years.
No, Biktarvy is currently brand-only. Patent protection expires Feb 7, 2033, after which generic versions may enter the market.
Medicare Part D spent $3.8B on Biktarvy, covering 85,000 beneficiaries across 1,020,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Check manufacturer patient assistance programs for potential savings. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Biktarvy's Medicare Pricing
At $3,746.00 per Medicare Part D claim, Biktarvy sits in specialty-drug territory — the price band occupied by biologics, injectables, and narrow-population treatments rather than everyday maintenance pills. Costs at this level usually trace to complex manufacturing, a patient population too small to spread fixed R&D across millions of scripts, or a class with no generic or biosimilar competition yet. For a drug treating hiv, that price is the single biggest lever on out-of-pocket exposure, which is why coverage tier and assistance eligibility matter far more here than for a commodity generic.
As a Medicare line item, Biktarvy is enormous: $3.8B in total Part D spending across 1,020,000 claims for 85,000 beneficiaries. At that scale the total is a product of both reach and price — a drug this widely prescribed at this cost is exactly the kind of molecule that draws CMS price-negotiation attention and PBM formulary leverage. The per-beneficiary figure, roughly $45K a year, is what translates the aggregate into an individual cost picture.
No generic competes with Biktarvy yet — patent protection runs to Feb 7, 2033, the date that matters most for its future price. Until then the savings levers are narrower: manufacturer copay assistance for those who qualify, discount-card pricing on cash-pay fills, and therapeutic substitution to a cheaper in-class option for hiv where one exists. The structural price drop arrives with generic entry, which historically pulls prices down 80–95% within a year or two of the patent cliff.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $3,746.00 as a consistent Medicare-program benchmark for Biktarvy, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Compare costs for other hiv medications
Compare 8 drugs in the HIV Antiretrovirals class
See every Gilead drug tracked by Medicare Part D
Top prescription drugs by Medicare spending
Drugs losing patent protection soon
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.